<DOC>
	<DOCNO>NCT01253811</DOCNO>
	<brief_summary>This trial conduct Asia , Europe United States America ( USA ) . The aim clinical trial investigate long-term safety rFXIII administer prevention bleed episode child age 1 6 year congenital FXIII A-subunit deficiency . This trial extension trial F13CD-3760 ( mentorâ„¢4 , NCT01230021 ) . If applicable trial extend maximum 3 year dependent recombinant factor XIII commercially available subject 's respective country use child 1-6 year age .</brief_summary>
	<brief_title>Safety Efficacy Monthly Replacement Therapy With Recombinant Factor XIII ( rFXIII ) Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Completed participation trial F13CD3760 ( NCT01230021 ) Known suspect hypersensitivity trial product related product Known history development inhibitor FXIII ( factor XIII ) Hereditary acquire coagulation disorder FXIII congenital deficiency Platelet count ( thrombocyte ) less 50X10e9 / L Previous history autoimmune disorder involve autoantibody e.g. , systemic lupus erythematosus Previous history arterial venous thromboembolic event e.g. , cerebrovascular accident deep vein thrombosis Any disease condition , judge trial physician , could imply potential hazard subject , interfere trial participation trial outcome include renal and/or liver dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>